← 返回前沿论文

从益气活血解毒方中分离外泌体样纳米囊泡及其抗卵巢癌活性

英文原题:Isolation of exosome-like nanovesicles from Yiqi Huoxue Jiedu decoction and their anti-ovarian cancer activity.

PubMed 2025/10/15(内容时间) Front Pharmacol Q1 · IF 5.4(JCR 2025)

研究概要

从YQHXJDD中分离的煎剂ELNVs能够抑制卵巢癌的生长和播散。这些ELNVs中包裹的miRNAs和脂质成分被认为是其抗卵巢癌作用的关键介质。

研究思路结论见上方概要

卵巢癌是最致命的妇科恶性肿瘤,以高复发率和不良预后为特征。源自中药复方煎剂的外泌体样纳米囊泡(ELNVs)包裹关键生物活性成分,并显示出有前景的治疗效果,具有良好的生物相容性和靶向能力。然而,关于ELNV提取方法的研究仍然有限。益气活血解毒汤(YQHXJDD)是一种经验证用于卵巢癌的中药复方,但目前缺乏对其ELNV分离方案和治疗机制的系统研究。本研究以YQHXJDD为研究对象,重点从该中药复方中提取ELNVs并验证其抗卵巢癌活性。

YQHXJDD采用不同的煎煮方案提取。ELNVs通过梯度和超速离心富集,重悬于磷酸盐缓冲液中,并使用透射电子显微镜(TEM)和纳米颗粒跟踪分析(NTA)对其粒径和浓度进行表征。计算每剂YQHXJDD富集的ELNVs数量,以筛选使ELNV产量最大化且符合临床用药实践的煎煮方法。通过zeta电位测量评估YQHXJDD ELNVs的胶体稳定性,并使用非靶向代谢组学和RNA测序鉴定YQHXJDD ELNVs的生物活性成分。建立ID8-Luc腹膜荷瘤小鼠模型,并随机分为三组:模型组、YQHXJDD组和YQHXJDD ELNVs组。小鼠连续灌胃3周。通过活体小动物成像监测肿瘤负荷。采用免疫荧光定量大网膜肿瘤中CD86、CD206、CD4和CD8荧光。使用Luminex xMAP® Multiplex Assay检测血清中36种细胞因子/趋化因子,并使用流式细胞术分析脾脏免疫细胞比例和活性。

在煎煮过程中形成的ELNVs,采用最佳方案时生成效率最高,该方案经鉴定可最大化YQHXJDD ELNVs产量,包括先高温处理40 min,再低温处理30 min。基于Zetaview的zeta电位分析表明,采用该方案制备的YQHXJDD ELNVs平均zeta电位为-35.52 mV,表明其具有良好的胶体稳定性。非靶向代谢组学分析显示,“脂质及类脂分子”是最丰富的代谢物超类(占总代谢物的34.98%),而“羧酸及其衍生物”是主要亚类(11.66%)。就小RNA而言,YQHXJDD ELNVs中富集的小RNA被证实为典型且具有功能活性的小RNA。值得注意的是,miR8783及其他miRNA表现出显著高表达,同时在样本间具有高度保守性和丰度,提示它们可能是YQHXJDD ELNVs生物学功能的核心调控因子。在体内评估中,与模型组相比,YQHXJDD ELNVs显著抑制卵巢癌生长和转移,提高小鼠外周血中肿瘤坏死因子-α(TNF-α)水平,并正向调节大网膜组织中M1/M2巨噬细胞比例和CD4 + /CD8 + T细胞比例(均P < 0.05)。然而,YQHXJDD ELNVs对脾脏效应T细胞、自然杀伤(NK)细胞、活化CD8 + T细胞和活化NK细胞的比例无显著影响(均P ≥ 0.05)。

展开英文摘要原文

BACKGROUND: Ovarian cancer, the deadliest gynecologic malignancy, is marked by high recurrence and poor prognosis. Exosome-like nanovesicles (ELNVs) derived from decocted traditional Chinese medicine (TCM) formulas encapsulate key bioactive components, and show promising therapeutic efficacy with good biocompatibility and targeting ability. However, research on ELNV extraction methodologies remains limited. Yiqi Huoxue Jiedu Decoction (YQHXJDD), an empirically validated TCM formula for ovarian cancer, lacks systematic investigation into its ELNV isolation protocols and therapeutic mechanisms. This study took YQHXJDD as the research subject, with a focus on extracting ELNVs from this TCM formula and validating their anti-ovarian cancer activity. METHODS: YQHXJDD was extracted using varied decoction protocols. ELNVs were enriched by gradient and ultracentrifugation, resuspended in phosphate-buffered saline, and were characterized by size and concentration using transmission electron microscopy (TEM) and nanoparticle tracking analysis (NTA). The number of ELNVs enriched per dose of YQHXJDD was calculated to screen the decoction method that maximized ELNV yield and aligned with clinical medication practices. The colloidal stability of YQHXJDD ELNVs was evaluated via zeta potential measurement, and the bioactive components of YQHXJDD ELNVs were identified using untargeted metabolomics and RNA sequencing. An ID8-Luc peritoneal tumor-bearing mouse model was established and randomized into three groups: model, YQHXJDD, and YQHXJDD ELNVs. Mice received oral gavage for 3 consecutive weeks. Tumor burden was monitored via in vivo small animal imaging. Immunofluorescence was used to quantify CD86, CD206, CD4, and CD8 fluorescence in omental tumors. Luminex xMAP® Multiplex Assay was used to detect 36 cytokines/chemokines in serum, and flow cytometry was used to analyze splenic immune cell proportions and activity. RESULTS: The creation efficiency of ELNVs formed during decoction is the highest with the optimal protocol, which is identified for maximizing YQHXJDD ELNV yield and involves 40 min of high-heat treatment followed by an additional 30 min of low-heat treatment. Zetaview-based zeta potential analysis demonstrated that YQHXJDD ELNVs by this protocol had an average zeta potential of -35.52 mV, indicating favorable colloidal stability. Untargeted metabolomics analysis revealed "Lipids and lipid-like molecules" as the most abundant metabolite superclass (34.98% of total metabolites), while "Carboxylic acids and derivatives" represented the dominant subclass (11.66%). Regarding small RNAs, those enriched in YQHXJDD ELNVs were confirmed to be typical, functionally active small RNAs. Notably, miR8783 and other miRNAs exhibited significantly high expression, along with high conservation and abundance across samples, suggesting they might act as core regulators of YQHXJDD ELNV biological functions. In in vivo assessments, compared with the model group, YQHXJDD ELNVs significantly inhibited ovarian cancer growth and metastasis, increased tumor necrosis factor-α (TNF-α) levels in mouse peripheral blood, and positively regulated the M1/M2 macrophage ratio and CD4 + /CD8 + T cell ratio in omental tissues (all P < 0.05). However, YQHXJDD ELNVs had no significant effect on the proportions of splenic effector T cells, natural killer (NK) cells, activated CD8 + T cells, and activated NK cells (all P ≥ 0.05). CONCLUSION: The decoction ELNVs isolated from YQHXJDD can inhibit the growth and dissemination of ovarian cancer. The miRNAs and lipid components encapsulated in these ELNVs are presumed to be the critical mediators of these anti-ovarian cancer effects.

论文信息

作者
Song QY、Cui YJ、Lu WP
单位
Department of Oncology, China Academy of Chinese Medical Sciences Guang'anmen Hospital, Beijing, China.China
期刊
Frontiers in pharmacology2025
原文标识
PubMed 41170390 · DOI 10.3389/fphar.2025.1680551